adalimumab + methotrexate + triamcinolone hexacetonide

A combination therapy used in a treat-to-target strategy for early rheumatoid arthritis. This regimen combines adalimumab (a TNF-α inhibitor), methotrexate (a conventional synthetic disease-modifying antirheumatic drug), and intra-articular triamcinolone hexacetonide (a glucocorticosteroid). The treatment protocol typically involves methotrexate (titrated to 20 mg/week), adalimumab (40 mg every other week), and intra-articular injections of triamcinolone hexacetonide (20 mg/ml) into swollen joints. This combination has been shown to effectively reduce disease activity, increase remission rates, and halt structural damage progression in early rheumatoid arthritis.